Trials / Recruiting
RecruitingNCT06007222
Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- OCEAN-SHD Study Group · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period. Non-antithrombotic group: No antithrombotic agents will be administered after randomization until the end of the study period.
Conditions
- Aortic Stenosis
- TAVI(Transcatheter Aortic Valve Implantation)
- Aspirin
- DAPT(Dual Antiplatelet Therapy)
- SAPT(Single Antiplatelet Therapy)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin group | Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period. |
| DRUG | Non-antithrombotic group | No antithrombotic agents will be administered after randomization until the end of the study period. |
Timeline
- Start date
- 2023-04-06
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
- First posted
- 2023-08-23
- Last updated
- 2024-09-23
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT06007222. Inclusion in this directory is not an endorsement.